Home » Authors » James Etheridge

James Etheridge

Articles

ARTICLES

Immutep Initiating Phase I IMP321 Breast Cancer Trial

Aug. 9, 2006

By James Etheridge

Immutep Initiating Phase I IMP321 Breast Cancer Trial

Aug. 9, 2006

By James Etheridge

NicOx To Initiate Two Phase II Trials Of NCX 4016 In Diabetes

Aug. 2, 2006

By James Etheridge

NicOx To Initiate Two Phase II Trials Of NCX 4016 In Diabetes

Aug. 2, 2006

By James Etheridge

Cellectis, Lexicon Genetics Exchange Rights To Patents

July 19, 2006

By James Etheridge

Cellectis, Lexicon Genetics Exchange Rights To Patents

July 19, 2006

By James Etheridge

LTKfarma Setting Up Shop With Product In Phase I/II

July 12, 2006

By James Etheridge

Eurofins Scientific Invests In Danish, Japanese Food Firms

July 12, 2006

By James Etheridge

Eurofins Scientific Invests In Danish, Japanese Food Firms

July 12, 2006

By James Etheridge

LTKfarma Setting Up Shop With Product In Phase I/II

July 12, 2006

By James Etheridge

View All Articles by James Etheridge

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 13, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 13, 2024.
Second insulin receptor offers new therapeutic avenues
BioWorld Science
Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...
Mechanism underlying so-called idiopathic autism inception unveiled
BioWorld Science
Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...
Keros stock wilts as it halts two dosing arms in hypertension study
BioWorld
After Keros Therapeutics Inc.’s voluntary halt of dosing in two arms of its phase II study in pulmonary arterial hypertension, the company’s stock crumpled after...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.